Epileptic Spasm clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • ZX008 in Subjects With CDKL5 Deficiency Disorder

    open to eligible people ages 1-35

    This is a multicenter, double-blind, parallel-group, placebo controlled, 2-part study to evaluate the efficacy and safety of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).

    Los Angeles, California and other locations

Our lead scientists for Epileptic Spasm research studies include .

Last updated: